Researchers at the Institute for Bioengineering of Catalonia and West China Hospital Sichuan University have developed a bioactive nanoparticle therapy that reverses Alzheimer’s disease pathology in mouse models. Unlike typical nanomedicine, which serves as drug carriers, these 'supramolecular drugs' directly modulate blood-brain barrier transport mechanisms, facilitating enhanced clearance of amyloid-β protein. The treatment restored cognitive function for up to six months post administration, offering a novel precision neurovascular medicine strategy targeting vascular contributions to Alzheimer's disease.